Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
SAN DIEGO and TORONTO, Aug. 03, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10th, 2017 at 11:30 a.m. ET at the Intercontinental Hotel, Boston, MA.
Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.
| Time: | 11:30 a.m. ET | ||||
| Date: | Thursday, August 10, 2017 | ||||
| Location: | Intercontinental Hotel, Boston, MA | ||||
A live webcast of the Aptose presentation will be accessible by visiting:
http://wsw.com/webcast/canaccord26/apto
The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] SMP Communications Susan Pietropaolo 201-923-2049 [email protected]
